CAR T-cell Therapy in AML: State of the Art

Get up to date on menin inhibitors, an emerging class of targeted therapies for acute myeloid leukemia (AML). Menin is a key component of the KMT2A (lysine methyltransferase 2A, formerly MLL1) complex, which plays a critical role in gene regulation, development, and cell cycle co ...  Show more

Get up to date with the EHA–ESMO guidelines on Human immunodeficiency virus (HIV)-associated Lymphomas. In this episode, Prof. Kai Hubel, a key author of the guidelines, explains the importance of having dedicated recommendations for patients with HIV-associated lymphomas. He beg ...  Show more

In today’s episode, we welcome back Dr. Amar Kelkar for part 2 of our two-part discussion on allogeneic transplant. In this episode, we build on our prior discussion regarding transplant, this time focusing on transp ...

This is the last episode of our core curriculum series. In this episode we discuss cancer survivorship as it relates to gynecologic oncology. Additionally we provide a framework for surveillance visits as well the general timing based on primary malignancy. We also give a brief o ...  Show more

This week, we continue talking about relapsed/refractory follicular lymphoma, this time focusing on cellular therapy options, namely bispecific agents and CAR T therapy. If you have not done so, we h ...

In this episode, Dr. Nazim Gherabi (DZ) discusses his systematic review on the treatment of urge incontinence in postmenopausal women.

Dr. Gherabi talks about the most effective therapeutic approaches, and evaluates current evidence. He highlights gaps in research and ...